Fibrinolysis Before Cardiopulmonary Bypass?

Completed · Phase 4 · Has a placebo group

Conditions studied: Pathologic Fibrinolysis

In brief

It is common practice to use antifibrinolytic agents before and during cardiopulmonary bypass. They are not without side effects. The investigators want to show that there is no proof of fibrinolysis in standard sternotomy cardiac surgery patients before cardiopulmonary bypass, and that antifibrinolytic agents should only be started on cardiopulmonary bypass.

Key facts

Study ID

NCT01981863

Run by

Stanford University

People needed

40

Starts

2013-07-01

Expected to finish

2014-02-01

Last updated by the study team

2016-06-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All adult patients, undergoing first time sternotomy for Coronary artery bypass grafting/Aortic valve replacement/aortic surgery

You may not qualify if…

• Resternotomy, renal insufficiency, deep hypothermia, age < 18 yrs

Where it is running

• Stanford Hospital & Clinics — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.